Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, requiring novel treatments to target both cancer cells and cancer stem cells (CSCs). Altered splicing is emerging as both a novel cancer hallmark and an attractive therapeutic target. The core splicing factor SF3B...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Emilia Alors-Perez, Ricardo Blázquez-Encinas, Sonia Alcalá, Cristina Viyuela-García, Sergio Pedraza-Arevalo, Vicente Herrero-Aguayo, Juan M. Jiménez-Vacas, Andrea Mafficini, Marina E. Sánchez-Frías, María T. Cano, Fernando Abollo-Jiménez, Juan A. Marín-Sanz, Pablo Cabezas-Sainz, Rita T. Lawlor, Claudio Luchini, Laura Sánchez, Juan M. Sánchez-Hidalgo, Sebastián Ventura, Laura Martin-Hijano, Manuel D. Gahete, Aldo Scarpa, Álvaro Arjona-Sánchez, Alejandro Ibáñez-Costa, Bruno Sainz, Raúl M. Luque, Justo P. Castaño
Format:	article
Langue:	EN
Publié:	BMC 2021
Sujets:	Pancreatic cancer Splicing-spliceosome SF3B1 Pladienolide-B cancer stem cells Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/2e57a0d7fd7f42d6a9f88e1c0cae6aca
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Documents similaires